👤 Longbo Hu

🔍 Search 📋 Browse 🏷️ Tags ❤️ Favourites ➕ Add 🧬 Extraction
921
Articles
642
Name variants
Also published as: Cheng-En Hu, Zhiqiang Hu, Xiao Hu, Sangyu Hu, Xiaoxia Hu, Yijia Hu, Li-Ling Hu, Min HU, Lanxin Hu, Yu-Sheng Hu, Lingmin Hu, Xue Hu, Chenghong Hu, Haitian Hu, Xiaolin Hu, An Hu, Ziwei Hu, Jessie J Hu, Lufeng Hu, Chang-Jiang Hu, Lidan Hu, Xixi Hu, Wenhui Hu, Mandong Hu, Xinyao Hu, Xingdi Hu, Qiao Hu, Chunmiao Hu, Chiao-Feng Hu, Kelly A Hu, Yali Hu, Jingjing Hu, Yang-Xi Hu, Jinxin Hu, Kaishun Hu, Xiaojing Hu, Fengqing Hu, Hong-Kang Hu, Jun Hu, Wenbo Hu, Chengyuan Hu, Linfeng Hu, Hong-Zhen Hu, Fangfang Hu, Tingxi Hu, Hanning Hu, Yepeng Hu, Liang Hu, Yujie Hu, Dingheng Hu, Lihong Hu, Chuanyin Hu, Tianyu Hu, Xinli Hu, Haitao Hu, Zuomin Hu, Pengfei Hu, Linglong Hu, Shichuan Hu, L-S Hu, Hao Hu, Da-Yi Hu, X Hu, Sai Hu, Zongyun Hu, Huaqing Hu, Dongjie Hu, Wei Hu, Yanqing Hu, Hongfeng Hu, Shan Hu, Zhilin Hu, Frank B Hu, Yameng Hu, Yushi Hu, Ronggui Hu, Shuang Hu, Xiangyu Hu, Frank Hu, Chang-Chen Hu, Chunli Hu, Zeping Hu, Haidai Hu, Jiafeng Hu, Zhonglan Hu, Wen Hu, Kunlong Hu, Guozhang Hu, Ji Hu, Lipeng Hu, G-X Hu, Limin Hu, Yating Hu, Jiahao Hu, Jin-Wu Hu, Fangdi Hu, Yinghui Hu, Wangxing Hu, Shiyan Hu, Zhengmao Hu, Xinyu Hu, Guoliang Hu, Chen Hu, Qilong Hu, Xiaozhi Hu, Shaofan Hu, Songjie Hu, Peizhen Hu, Xiao-Hui Hu, Xinrong Hu, Anyi Hu, Zhangxue Hu, Dayi Hu, Yueming Hu, Hai Hu, Ya-Hui Hu, Hui-Jun Hu, Nan Hu, Hongling Hu, Zhixing Hu, Zhijie Hu, Yingying Hu, Xiaowen Hu, Erqiang Hu, Danhui Hu, Simin Hu, Xueda Hu, Haochang Hu, Mengjie Hu, Zengyun Hu, Xiaobin Hu, Su-Wei Hu, Kai Hu, Yangfan Hu, Ting Hu, Zuojian Hu, Xiaofeng Hu, Yunyan Hu, Wenxin Hu, Chuan Hu, Jiqiang Hu, Bo Hu, Jie Hu, Zhi-bin Hu, Guangyu Hu, Tingwei Hu, Yuqiu Hu, Fang-Wei Hu, Xintao Hu, Jianping Hu, Chaoqun Hu, Hu Hu, Jia Hu, Qinghua Hu, Qinwen Hu, Zizhong Hu, Shangfeng Hu, Yuxin Hu, Liangyu Hu, Chunyu Hu, Guoxin Hu, Xiaoyu Hu, Jiayin Hu, Canrun Hu, Junkai Hu, Jun-Yi Hu, Panyang Hu, Guang Hu, Die Hu, Saiyang Hu, Yu-Feng Hu, Krista Y Hu, Xinyue Hu, Xuan Hu, Chenming Hu, J W Hu, Fenghua Hu, Zhao-Yang Hu, Shi-Jun Hu, Min-shan Hu, Xuesong Hu, Su Hu, Shenqiang Hu, Yiqing Hu, Dahai Hu, Bang Hu, Yiping Hu, Miao-Lin Hu, C Hu, Zhiyong Hu, Hanguang Hu, Jiabao Hu, Yuexin Hu, Ruiyao Hu, Deming Hu, Yu-Ting Hu, Panpan Hu, Jia-Wei Hu, Zhuang-Li Hu, Xiangrong Hu, Yutian Hu, Xinyuan Hu, Sen-Lin Hu, Xu Hu, Yihan Hu, Yiguo Hu, Baifei Hu, Fangbo Hu, Hanmeng Hu, Kevin Hu, Xujuan Hu, Yi-Ping Hu, Guohong Hu, F Hu, Suqing Hu, Lian Hu, Huimin Hu, Liyan Hu, Tianqi Hu, Allison C Hu, Zhang-Xue Hu, Xiaoxiao Hu, Lijuan Hu, Xinglv Hu, Yonggang Hu, Chao-Yu Hu, Yingchao Hu, Li Hu, Xiaoyue Hu, Mi Hu, Bo-Ang Hu, Haicheng Hu, Qiaomu Hu, Yue Hu, Chun-Ting Hu, Wan-Chung Hu, Junjie Hu, Juan Hu, Zan Hu, Yi-Xuan Hu, Zheng-Mao Hu, Alex Hu, Qiping Hu, Fang Hu, Jin-Xia Hu, Xiangyang Hu, Bolang Hu, Meilin Hu, Shun Hu, Yanjie Hu, X H Hu, Xia Hu, Huan Hu, Qihao Hu, Hong Hu, Xue-Mei Hu, Yuepeng Hu, Aoni Hu, Yanyu Hu, Yousheng Hu, Bangchuan Hu, Limei Hu, Shilei Hu, Lifang Hu, Kefan Hu, Zhongyao Hu, Donglei Hu, Bing Hu, Nengwei Hu, Chun-Yan Hu, Shu-Mei Hu, Yongwu Hu, Gang Hu, Jiangbo Hu, Weihua Hu, Yunzhang Hu, Ling Hu, Patrick Hu, Zhenying Hu, Ruozhen Hu, Guomin Hu, Ye Hu, Yi-Peng Hu, Bin Hu, Liu-Bing Hu, Lei Hu, Shuiqing Hu, Xiao-Hong Hu, Ya-Li Hu, Yukai Hu, Chengyi Hu, Xiao-Hua Hu, Jintao Hu, Xiaosong Hu, Liyuan Hu, Xiangjun Hu, Xianjing Hu, Sanyuan Hu, Manqiu Hu, Die-Fei Hu, Naifan Hu, Mingzhao Hu, Jianfei Hu, Zhibin Hu, Xiang Hu, Xinting Hu, Xiaodi Hu, Yan-wei Hu, Dorothy Hu, Zhiying Hu, Linda Hu, Guodong Hu, Yunhua Hu, Sunkuan Hu, Jianhong Hu, Zhengping Hu, Chunyan Hu, Danjie Hu, Wen-Ting Hu, Yejia Hu, Zhenhua Hu, Yingjie Hu, Ya-Yu Hu, Yanling Hu, Zhiquan Hu, Jingwen Hu, Yao Hu, Changyuan Hu, Yue-Xiao Hu, Yuan Hu, Xin-Sheng Hu, Zhijun Hu, Xin Hu, Beijuan Hu, Ruolan Hu, Jin Hu, Bei Hu, Qin Hu, Xiaodan Hu, Michele T M Hu, Xiao-Meng Hu, Xiaojuan Hu, Huiming Hu, Zhongke Hu, Shaohua Hu, Yingchun Hu, Shihe Hu, Hairong Hu, Jingchu Hu, Jianying Hu, Haijian Hu, Haijuan Hu, Na Hu, Yuehong Hu, Ming Hu, Y Hu, Haiyan Hu, Zuli Hu, Ya-Rong Hu, Jiapeng Hu, Jinxing Hu, Yiwen Hu, Jiewei Hu, Yuanyuan Hu, Cheng Hu, Manli Hu, Xueli Hu, Li-Yuan Hu, Chengxiang Hu, Jun-ping Hu, Tongyuan Hu, Ying-Jie Hu, Pengzhen Hu, Yueqiang Hu, Y H Hu, Houyuan Hu, Wenhao Hu, Fei Hu, Jinghua Hu, Jian Hu, Jinwu Hu, XueLie Hu, Weipeng Hu, Qiaoling Hu, Ying Hu, Changhua Hu, Zhizhou Hu, Mingxin Hu, William T Hu, Xiaohui Hu, Xiaohu Hu, Guo-Xin Hu, Yaodong Hu, Xiaomei Hu, Yejun Hu, Ke Hu, Xue-Qun Hu, Baoyang Hu, Haoxiang Hu, Haochong Hu, Desheng Hu, Dongyu Hu, Xiaotong Hu, Zhaoting Hu, Kexin Hu, Baihua Hu, Jessica Hu, Shanshan Hu, Chengcheng Hu, Yu-Qi Hu, Zixuan Hu, Qianying Hu, Qiulan Hu, Jianyong Hu, Boran Hu, Xun Hu, Chi-Tan Hu, Jinying Hu, Yijun Hu, Shengshou Hu, Meng Hu, Han Hu, Xiqi Hu, Yongxian Hu, Shourui Hu, Fudong Hu, Cong Hu, Xingwang Hu, Ai-Min Hu, Yongbin Hu, Guo Liang Hu, Wenjing Hu, Yulian Hu, Minghui Hu, Ping Hu, Daixing Hu, Yan Hu, Zhigang Hu, Jingqing Hu, Qian Hu, Yong Hu, Meng-Meng Hu, Miaoyang Hu, Rui Hu, Hua Hu, Z Hu, Wen-Cheng Hu, Aiyan Hu, D Y Hu, Cheng-Jun Hu, Junhao Hu, Jiayu Hu, Bing-Xuan Hu, Qun Hu, Anpei Hu, Senlin Hu, Keqing Hu, Xiujing Hu, Weiwen Hu, Fan Hu, Xiaorong Hu, Anqi Hu, Yongfei Hu, Xiaofei Hu, Zhenbo Hu, Keping Hu, Ziyang Hu, Junbo Hu, Xiu-Wei Hu, Y-K Hu, Ning Hu, Xue-Jian Hu, Fangzhu Hu, Xuefeng Hu, Ruoxi Hu, Xinyi Hu, Yongjun Hu, Chunfeng Hu, Haifeng Hu, Yanjun Hu, Jichao Hu, Zheng Hu, B Hu, Ran Hu, Zelin Hu, Jianran Hu, Jiahe Hu, Xiaoyan Hu, Yang Hu, Shimin Hu, Qiyuan Hu, Kuan Hu, Jingjie Hu, Ziliang Hu, Yaxin Hu, Zhijian Hu, Weiquan Hu, Xiaoli Hu, Guo-Han Hu, Yuanlong Hu, Changqing Hu, Yiying Hu, Tiffany Hu, Guangdong Hu, Xiao-Ping Hu, Jerry Hu, Yibo Hu, Yuhong Hu, Jinlin Hu, Kai-Lun Hu, Xianzhe Hu, Chang Hu, Jiemiao Hu, Donghua Hu, Zhuo-Wei Hu, Xian Gui Hu, Hongjia Hu, Changchen Hu, Zhi-Qiang Hu, Jiejun Hu, Lulu Hu, Lilin Hu, Hanze Hu, Boli Hu, Jianpeng Hu, Cegui Hu, Mengting Hu, Haigang Hu, Yue-Qin Hu, Shixian Hu, Jimeng Hu, Jinhua Hu, Xiang-Yang Hu, Yi Hu, Dandan Hu, Yun Hu, Lina Hu, Tianxiang Hu, Yue-Peng Hu, Zhangli Hu, Junting Hu, Jiaqiang Hu, Xiangyou Hu, Renjie Hu, Shudong Hu, Yaofei Hu, Yanhui Hu, Qile Hu, Shoudi Hu, Jiayao Hu, Qiongdan Hu, Hangqi Hu, Di Hu, Ningning Hu, Dan Hu, Xiaoshan Hu, Xiao-Lin Hu, Wanli Hu, Sean Hu, Tongtong Hu, Qisheng Hu, Yu Hu, Xiwen Hu, Zhiyuan Hu, Zhenguo Hu, Shiyi Hu, Pingzhao Hu, Haoyu Hu, Guo Hu, Li-Fang Hu, Xiao-Lei Hu, Song Hu, Chang-Hua Hu, Qubai Hu, Dong Hu, Sile Hu, Xiaoxiang Hu, Jiwei Hu, Qi Hu, Jiaxin Hu, Shuyuan Hu, Jiang Hu, Jing Hu, Teng Hu, Tingting Hu, Feng Hu, Yefan Hu, Weiyu Hu, Wenji Hu, Wenxiang Hu, Qing Hu, Miao Hu, Wangxiong Hu, Gangqing Hu, Biao Hu, Dingtao Hu, Shiyu Hu, Shuqi Hu, Chaowei Hu, Yunlu Hu, Yuwen Hu, Piaopiao Hu, Pin Hu, Xiucai Hu, Weiming Hu, Yaozhong Hu, Yao-Min Hu, Gui-Rong Hu, Zhen Hu, Aoling Hu, Yiyang Hu, Zhaoyong Hu, Qiaoguan Hu, Wentao Hu, Yinping Hu, He-Ping Hu, Yulong Hu, Junchi Hu, Chunhua Hu, Yiming Hu, Xiaojun Hu, Hongbo Hu, Huiyu Hu, Yeguang Hu, Tianyi Hu, Zhi-De Hu, Bodan Hu, Youna Hu, Chengkai Hu, Yunying Hu, Jia-Qiang Hu, Bingfang Hu, An-Kang Hu, Xuan-Yu Hu, Sung-Lin Hu, Shen Hu, Tingyan Hu, Xiaomin Hu, L W Hu, Jiawen Hu, Yuanhui Hu
articles
Guo-Xin Hu, Guang Liang, Yanhui Chu +7 more · 2010 · Bioorganic & medicinal chemistry letters · Elsevier · added 2026-04-24
Non-steroidal compounds that inhibit 17beta-hydroxysteroid dehydrogenase isoform 3 (17beta-HSD3), an enzyme catalyzing the final step in testosterone biosynthesis in Leydig cells, are under developmen Show more
Non-steroidal compounds that inhibit 17beta-hydroxysteroid dehydrogenase isoform 3 (17beta-HSD3), an enzyme catalyzing the final step in testosterone biosynthesis in Leydig cells, are under development for male contraceptive or treatment of androgen dependent diseases including prostate cancer. A series of curcumin analogues with more stable chemical structures were compared to curcumin as inhibitors of 17beta-HSD3 in rat intact Leydig cells as well as rat and human testis microsomes. Show less
no PDF DOI: 10.1016/j.bmcl.2010.02.089
HSD17B12
Xing Zuo, Hong Jiang, Ji-Feng Guo +10 more · 2010 · Neuroscience letters · Elsevier · added 2026-04-24
Two markers rs9652490 and rs11856808 both located in intron 3 of the LINGO1 gene have been nominated recently to be associated with essential tremor (ET). Although ET and Parkinson's disease (PD) are Show more
Two markers rs9652490 and rs11856808 both located in intron 3 of the LINGO1 gene have been nominated recently to be associated with essential tremor (ET). Although ET and Parkinson's disease (PD) are considered as different entities, they have many overlapping clinical and pathological features. We aimed to evaluate the role of rs9652490 and rs11856808 in the development of ET and PD. To this point, we sequenced the region involving the two markers in 109 ET cases, 425 sporadic Parkinson's disease (SPD) cases and 430 controls in Chinese population. After stratification by age, the rs9652490G allele suggested protective role in the early onset PD (EOPD, age at onset < or =50 years) group compared with age matched controls (OR=0.56, 95% CI: 0.35-0.90, p=0.015). No other significant association was found. We concluded that the two markers rs9652490 and rs11856808 were not strongly related to the development of ET or late onset SPD, but the rs9652490G allele might be a protective factor for EOPD in Chinese population. Show less
no PDF DOI: 10.1016/j.neulet.2010.06.041
LINGO1
Qing-Ling Fu, Bing Hu, Xin Li +5 more · 2010 · The European journal of neuroscience · Blackwell Publishing · added 2026-04-24
The antagonism of LINGO-1, a CNS-specific negative regulator of neuronal survival, was shown to promote short-term survival of retinal ganglion cell (RGC) in an ocular hypertension model. LINGO-1 anta Show more
The antagonism of LINGO-1, a CNS-specific negative regulator of neuronal survival, was shown to promote short-term survival of retinal ganglion cell (RGC) in an ocular hypertension model. LINGO-1 antagonists, combined with brain-derived neurotrophic factor (BDNF), can increase the length of neuron survival through an unclear molecular mechanism. To determine the relationship between LINGO-1 and BDNF/TrkB receptor in neuronal protection, we show here that LINGO-1 forms a receptor complex with TrkB and negatively regulates its activation in the retina after ocular hypertension injury. LINGO-1 antagonist antibody 1A7 or soluble LINGO-1 (LINGO-1-Fc) treatment upregulates phospho-TrkB phosphorylation and leads to RGC survival after high intraocular pressure injury. This neuronal protective effect was blocked by anti-BDNF antibody. LINGO-1 antagonism therefore promotes RGC survival by regulating the BDNF and TrkB signaling pathway after ocular hypertension. Show less
no PDF DOI: 10.1111/j.1460-9568.2010.07127.x
LINGO1
Jun Lv, Ru-xiang Xu, Xiao-dan Jiang +8 more · 2010 · Neuroimmunomodulation · added 2026-04-24
LINGO-1 (leucine-rich repeat and Ig domain-containing, Nogo receptor-interacting protein) is an important component of the NgR receptor complex involved in RhoA activation and axon regeneration. The a Show more
LINGO-1 (leucine-rich repeat and Ig domain-containing, Nogo receptor-interacting protein) is an important component of the NgR receptor complex involved in RhoA activation and axon regeneration. The authors report on passive immunization with LINGO-1 polyclonal antiserum, a therapeutic approach to overcome NgR-mediated growth inhibition after spinal cord injury (SCI). The intrathecally administered high-titer rabbit-derived antiserum can be detected around the injury site within a wide time window; it blocks LINGO-1 in vivo with high molecular specificity. In this animal model, passive immunization with LINGO-1 antiserum significantly decreased RhoA activation and increased neuronal survival. Adult rats immunized in this manner show recovery of certain hindlimb motor functions after dorsal hemisection of the spinal cord. Thus, passive immunotherapy with LINGO-1 polyclonal antiserum may represent a promising repair strategy following acute SCI. Show less
no PDF DOI: 10.1159/000290043
LINGO1
Wei Yan, Tongxin Zhang, Jun Cheng +3 more · 2010 · Pharmacology · added 2026-04-24
Liver X receptors (LXRs) promote macrophage reverse cholesterol transport and cholesterol excretion from the body. The synthetic LXR ligands T0901317 and GW3965 were shown to significantly inhibit ath Show more
Liver X receptors (LXRs) promote macrophage reverse cholesterol transport and cholesterol excretion from the body. The synthetic LXR ligands T0901317 and GW3965 were shown to significantly inhibit atherosclerosis in mice and to increase the expression of ATP-binding cassette transporter A1 (ABCA1) in the atherosclerotic lesions. However, these compounds increase plasma and hepatic triglyceride (TG) levels in mice. Methyl-3β-hydroxy-5α,6α-epoxycholanate (MHEC), synthesized from hyodeoxycholic acid, functions as an LXR agonist, but its role in atherogenesis and lipid metabolism remained to be elucidated. THP-1-derived macrophages were cultured in the medium con- taining various concentrations of MHEC or T0901317 (0-10 μmol/l) for 24 h. Reverse transcription polymerase chain reaction was used to quantify LXRα, LXRβ and ABCA1 mRNA levels in macrophages. Additionally, MHEC or T0901317 was orally administered at 10 mg/kg daily for 6 weeks in apolipoprotein E knockout (apoE⁻/⁻) mice fed a high-cholesterol diet. Plasma lipids were determined enzymatically. The area of and ABCA1 expression in the aortic atherosclerotic lesions were measured by oil red O staining and immunohistochemistry, respectively. Both MHEC and T0901317 equally stimulated LXRα and ABCA1 mRNA expression in a dose-dependent manner in THP-1-derived macrophages, but they did not induce LXRβ mRNA expression significantly. The plasma levels of total cholesterol, TG and high-density lipoprotein cholesterol were significantly higher in T0901317-treated mice than in the vehicle-treated control group. Interestingly, MHEC treatment dramatically increased plasma high-density lipoprotein cholesterol without altering plasma levels of total cholesterol and TG. Both MHEC and T0901317 equally inhibited the development of atherosclerotic lesions in apoE⁻/⁻ mice. The expression of ABCA1, a cholesterol efflux transporter, was greatly induced by the two LXR agonists in the artery wall. MHEC is a novel LXR agonist and it inhibits atherosclerosis in apoE⁻/⁻ mice without raising blood TG. Thus, MHEC relative to T0901317 may be a better therapeutic LXR agonist for the treatment of atherosclerosis. Show less
no PDF DOI: 10.1159/000321320
NR1H3
Baihua Hu, Rayomand J Unwalla, Igor Goljer +9 more · 2010 · Journal of medicinal chemistry · ACS Publications · added 2026-04-24
A series of phenyl sulfone substituted quinoxaline were prepared and the lead compound 13 (WYE-672) was shown to be a tissue selective LXR Agonist. Compound 13 demonstrated partial agonism for LXRbeta Show more
A series of phenyl sulfone substituted quinoxaline were prepared and the lead compound 13 (WYE-672) was shown to be a tissue selective LXR Agonist. Compound 13 demonstrated partial agonism for LXRbeta in kidney HEK-293 cells but did not activate Gal4 LXRbeta fusion proteins in huh-7 liver cells. Although 13 showed potent binding affinity to LXRbeta (IC(50) = 53 nM), it had little binding affinity for LXRalpha (IC(50) > 1.0 microM) and did not recruit any coactivator/corepressor peptides in the LXRalpha multiplex assay. However, compound 13 showed good agonism in THP-1 cells with respect to increasing ABCA1 gene expression and good potency on cholesterol efflux in THP-1 foam cells. In an eight-week lesion study in LDLR -/- mice, compound 13 showed reduction of aortic arch lesion progression and no plasma or hepatic triglyceride increase. These results suggest quinoxaline 13 may have an improved biological profile for potential use as a therapeutic agent. Show less
no PDF DOI: 10.1021/jm100034x
NR1H3
Yan-wei Hu, Lei Zheng, Qian Wang · 2010 · Clinica chimica acta; international journal of clinical chemistry · Elsevier · added 2026-04-24
Cellular cholesterol levels reflect a balance between uptake, efflux, and endogenous synthesis. The sterol-responsive transcription factors liver X receptors (LXRalpha and LXRbeta) help maintain chole Show more
Cellular cholesterol levels reflect a balance between uptake, efflux, and endogenous synthesis. The sterol-responsive transcription factors liver X receptors (LXRalpha and LXRbeta) help maintain cholesterol homeostasis, not only through promotion of cholesterol efflux from peripheral tissues but also through suppression of de novo synthesis and exogenous cholesterol uptake. In this review, we summarize the important role of LXRs in regulating expression of key members that keep cholesterol levels in balance. Show less
no PDF DOI: 10.1016/j.cca.2009.12.027
NR1H3
Yan-wei Hu, Qian Wang, Xin Ma +6 more · 2010 · Journal of atherosclerosis and thrombosis · added 2026-04-24
High density lipoprotein (HDL) and its apolipoproteins can promote cholesterol efflux from macrophage foam cells via the ATP-binding cassette transporter A1 (ABCA1), ABCG1, and scavenger receptor clas Show more
High density lipoprotein (HDL) and its apolipoproteins can promote cholesterol efflux from macrophage foam cells via the ATP-binding cassette transporter A1 (ABCA1), ABCG1, and scavenger receptor class B type I (SR-BI). Liver X receptors (LXRs) operate as cholesterol sensors which may protect from cholesterol overload by stimulating cholesterol efflux from cells to HDL through ABCA1, ABCG1 and SR-BI. The regulation of ABCA1, ABCG1 and SR-BI expression by cytokines present within the microenvironment of the atheroma may play an important role in determining the impact of reverse cholesterol transport on the atherosclerotic lesion. In the current study, we examined the effect of transforming growth factor-beta1 (TGF-beta1) on expressions of ABCA1, ABCG1 and SR-BI and explored the role of LXR alpha in the regulation of ABCA1, ABCG1 and SR-BI in THP-1 macrophage-derived foam cells. TGF-beta1 significantly increased expressions of ABCA1, ABCG1 and SR-BI at both transcriptional and translational levels in a dose-dependent and time-dependent manner. Cellular cholesterol content was decreased while cholesterol efflux was increased by TGF-beta1 treatment. Moreover, LXR alpha was up-regulated by TGF-beta1 treatment. In addition, LXR alpha small interfering RNA completely abolished the promotion effect induced by TGF-beta1. These results provide evidence that TGF-beta1 up-regulates expressions of ABCA1, ABCG1 and SR-BI through the LXR alpha pathway in THP-1 macrophage-derived foam cells. Show less
no PDF DOI: 10.5551/jat.3152
NR1H3
Baihua Hu, Ron Bernotas, Rayomand Unwalla +8 more · 2010 · Bioorganic & medicinal chemistry letters · Elsevier · added 2026-04-24
A series of quinoline-3-carboxamide containing sulfones was prepared and found to have good binding affinity for LXRbeta and moderate binding selectivity over LXRalpha. The 8-Cl quinoline analog 33 wi Show more
A series of quinoline-3-carboxamide containing sulfones was prepared and found to have good binding affinity for LXRbeta and moderate binding selectivity over LXRalpha. The 8-Cl quinoline analog 33 with a high TPSA score, displayed 34-fold binding selectivity for LXRbeta over LXRalpha (LXRbeta IC(50)=16nM), good activity for inducing ABCA1 gene expression in a THP macrophage cell line, desired weak potency in the LXRalpha Gal4 functional assay, and low blood-brain barrier penetration in rat. Show less
no PDF DOI: 10.1016/j.bmcl.2009.11.062
NR1H3
Cathy E Elks, John R B Perry, Patrick Sulem +172 more · 2010 · Nature genetics · Nature · added 2026-04-24
Cathy E Elks, John R B Perry, Patrick Sulem, Daniel I Chasman, Nora Franceschini, Chunyan He, Kathryn L Lunetta, Jenny A Visser, Enda M Byrne, Diana L Cousminer, Daniel F Gudbjartsson, Tõnu Esko, Bjarke Feenstra, Jouke-Jan Hottenga, Daniel L Koller, Zoltán Kutalik, Peng Lin, Massimo Mangino, Mara Marongiu, Patrick F McArdle, Albert V Smith, Lisette Stolk, Sophie H van Wingerden, Jing Hua Zhao, Eva Albrecht, Tanguy Corre, Erik Ingelsson, Caroline Hayward, Patrik K E Magnusson, Erin N Smith, Shelia Ulivi, Nicole M Warrington, Lina Zgaga, Helen Alavere, Najaf Amin, Thor Aspelund, Stefania Bandinelli, Inês Barroso, Gerald S Berenson, Sven Bergmann, Hannah Blackburn, Eric Boerwinkle, Julie E Buring, Fabio Busonero, Harry Campbell, Stephen J Chanock, Wei Chen, Marilyn C Cornelis, David Couper, Andrea D Coviello, Pio d'Adamo, Ulf de Faire, Eco J C de Geus, Panos Deloukas, Angela Döring, George Davey Smith, Douglas F Easton, Gudny Eiriksdottir, Valur Emilsson, Johan Eriksson, Luigi Ferrucci, Aaron R Folsom, Tatiana Foroud, Melissa Garcia, Paolo Gasparini, Frank Geller, Christian Gieger, GIANT Consortium, Vilmundur Gudnason, Per Hall, Susan E Hankinson, Liana Ferreli, Andrew C Heath, Dena G Hernandez, Albert Hofman, Frank B Hu, Thomas Illig, Marjo-Riitta Järvelin, Andrew D Johnson, David Karasik, Kay-Tee Khaw, Douglas P Kiel, Tuomas O Kilpeläinen, Ivana Kolcic, Peter Kraft, Lenore J Launer, Joop S E Laven, Shengxu Li, Jianjun Liu, Daniel Levy, Nicholas G Martin, Wendy L McArdle, Mads Melbye, Vincent Mooser, Jeffrey C Murray, Sarah S Murray, Michael A Nalls, Pau Navarro, Mari Nelis, Andrew R Ness, Kate Northstone, Ben A Oostra, Munro Peacock, Lyle J Palmer, Aarno Palotie, Guillaume Paré, Alex N Parker, Nancy L Pedersen, Leena Peltonen, Craig E Pennell, Paul Pharoah, Ozren Polasek, Andrew S Plump, Anneli Pouta, Eleonora Porcu, Thorunn Rafnar, John P Rice, Susan M Ring, Fernando Rivadeneira, Igor Rudan, Cinzia Sala, Veikko Salomaa, Serena Sanna, David Schlessinger, Nicholas J Schork, Angelo Scuteri, Ayellet V Segrè, Alan R Shuldiner, Nicole Soranzo, Ulla Sovio, Sathanur R Srinivasan, David P Strachan, Mar-Liis Tammesoo, Emmi Tikkanen, Daniela Toniolo, Kim Tsui, Laufey Tryggvadottir, Jonathon Tyrer, Manuela Uda, Rob M Van Dam, Joyce B J van Meurs, Peter Vollenweider, Gerard Waeber, Nicholas J Wareham, Dawn M Waterworth, Michael N Weedon, H Erich Wichmann, Gonneke Willemsen, James F Wilson, Alan F Wright, Lauren Young, Guangju Zhai, Wei Vivian Zhuang, Laura J Bierut, Dorret I Boomsma, Heather A Boyd, Laura Crisponi, Ellen W Demerath, Cornelia M Van Duijn, Michael J Econs, Tamara B Harris, David J Hunter, Ruth J F Loos, Andres Metspalu, Grant W Montgomery, Paul M Ridker, Tim D Spector, Elizabeth A Streeten, Kari Stefansson, Unnur Thorsteinsdottir, André G Uitterlinden, Elisabeth Widen, Joanne M Murabito, Ken K Ong, Anna Murray Show less
To identify loci for age at menarche, we performed a meta-analysis of 32 genome-wide association studies in 87,802 women of European descent, with replication in up to 14,731 women. In addition to the Show more
To identify loci for age at menarche, we performed a meta-analysis of 32 genome-wide association studies in 87,802 women of European descent, with replication in up to 14,731 women. In addition to the known loci at LIN28B (P = 5.4 × 10⁻⁶⁰) and 9q31.2 (P = 2.2 × 10⁻³³), we identified 30 new menarche loci (all P < 5 × 10⁻⁸) and found suggestive evidence for a further 10 loci (P < 1.9 × 10⁻⁶). The new loci included four previously associated with body mass index (in or near FTO, SEC16B, TRA2B and TMEM18), three in or near other genes implicated in energy homeostasis (BSX, CRTC1 and MCHR2) and three in or near genes implicated in hormonal regulation (INHBA, PCSK2 and RXRG). Ingenuity and gene-set enrichment pathway analyses identified coenzyme A and fatty acid biosynthesis as biological processes related to menarche timing. Show less
no PDF DOI: 10.1038/ng.714
SEC16B
Jiajun Shi, Jirong Long, Yu-Tang Gao +9 more · 2010 · American journal of epidemiology · Oxford University Press · added 2026-04-24
Recent genome-wide association (GWA) studies have identified 18 genetic loci for obesity. Using directly observed and imputed GWA genotyping data on approximately 5,000 Chinese women (1996-2007), the Show more
Recent genome-wide association (GWA) studies have identified 18 genetic loci for obesity. Using directly observed and imputed GWA genotyping data on approximately 5,000 Chinese women (1996-2007), the authors evaluated 17 single nucleotide polymorphisms (SNPs) that represent 17 distinct obesity loci. Two SNPs near the BAT2 and MC4R genes and 3 SNPs within the FTO, SEC16B, and SH2B1 genes were significantly associated with body mass index (weight (kg)/height (m)(2)), body weight, and the prevalence of obesity. The per-allele increase in body mass index ranged from 0.16 units (BAT2) to 0.38 units (SH2B1). Odds ratios for obesity ranged from 1.46 (95% confidence interval (CI): 1.12, 1.92) for BAT2 to 2.16 (95% CI: 1.39, 3.37) for MC4R. A genetic risk score calculated by summing the number of risk-increasing alleles that each woman carried at these 5 loci was significantly associated with the prevalence of obesity. Women carrying 5 or more risk alleles had a 3.13-fold (95% CI: 2.06, 4.77) higher prevalence of obesity than women carrying 1 or no risk alleles. Results from this study extend some previous GWA findings to Chinese women and show the need for additional studies to identify susceptibility loci in Chinese and other Asian populations. Show less
no PDF DOI: 10.1093/aje/kwq129
SEC16B
Xian-sheng HUANG, Shui-ping ZHAO, Qian ZHANG +3 more · 2009 · Zhonghua xin xue guan bing za zhi · added 2026-04-24
To explore the relationship between serum apolipoprotein A5 (ApoA5) and lipid profile or high sensitive C-reactive protein (hs-CRP) in patients with acute coronary syndrome (ACS). Serum apoA5 and hs-C Show more
To explore the relationship between serum apolipoprotein A5 (ApoA5) and lipid profile or high sensitive C-reactive protein (hs-CRP) in patients with acute coronary syndrome (ACS). Serum apoA5 and hs-CRP levels were measured by ELISA and immunoturbidimetry in control subjects (n = 232), patients with stable angina (SA, n = 127), unstable angina (UA, n = 116) and acute myocardial infarction (AMI, n = 112). Triglyceride (TG), total cholesterol (TC), high density lipoprotein cholesterol (HDL-C) and low density lipoprotein cholesterol (LDL-C) were also measured. Compared with controls [(108.7 +/- 23.2) microg/L] and SA patients [(78.3 +/- 20.2) microg/L], serum ApoA5 level was significantly increased in UA [(340.6 +/- 63.5) microg/L] and AMI patients [(373.2 +/- 73.8) microg/L] (all P < 0.05). ApoA5 was positively correlated with TG (r = 0.63 and 0.67, respectively, all P < 0.05) and hs-CRP (r = 0.57 and 0.55, respectively, all P < 0.05) in UA and AMI patients but there were no significant correlations between ApoA5 and TC, HDL-C and LDL-C in ACS patients (all P > 0.05). Increased serum apoA5 level and the positive correlation between ApoA5 and serum TG and hs-CRP in ACS patients might reflect increased inflammation responses in ACS patients. Show less
no PDF
APOA5
Xian-sheng HUANG, Shui-ping ZHAO, Lin BAI +3 more · 2009 · British journal of pharmacology · Blackwell Publishing · added 2026-04-24
Combining statin and fibrate in clinical practice provides a greater reduction of triglycerides than either drug given alone, but the mechanism for this effect is poorly understood. Apolipoprotein AV Show more
Combining statin and fibrate in clinical practice provides a greater reduction of triglycerides than either drug given alone, but the mechanism for this effect is poorly understood. Apolipoprotein AV (apoAV) has been implicated in triglyceride metabolism. This study was designed to investigate the effect of the combination of statin and fibrate on apoAV and the underlying mechanism(s). Hypertriglyceridaemia was induced in rats by giving them 10% fructose in drinking water for 2 weeks. They were then treated with atorvastatin, fenofibrate or the two agents combined for 4 weeks, and plasma triglyceride and apoAV measured. We also tested the effects of these two agents on triglycerides and apoAV in HepG2 cells in culture. Western blot and reverse transcription polymerase chain reaction was used to measure apoAV and peroxisome proliferator-activated receptor-alpha (PPARalpha) expression. The combination of atorvastatin and fenofibrate resulted in a greater decrease in plasma triglycerides and a greater increase in plasma and hepatic apoAV than either agent given alone. Hepatic expression of the PPARalpha was also more extensively up-regulated in rats treated with the combination. A similar, greater increase in apoAV and a greater decrease in triglycerides were observed following treatment of HepG2 cells pre-exposed to fructose), with the combination. Adding an inhibitor of PPARalpha (MK886) abolished the effects of atorvastatin on HepG2 cells. A combination of atorvastatin and fenofibrate increased apoAV and decreased triglycerides through up-regulation of PPARalpha. Show less
no PDF DOI: 10.1111/j.1476-5381.2009.00350.x
APOA5
Xian-sheng HUANG, Shui-ping ZHAO, Qian ZHANG +2 more · 2009 · Chinese medical journal · added 2026-04-24
Increased triglyceride (TG) occurs in patients with acute coronary syndrome (ACS), and apolipoprotein AV (apoAV) has been shown to lower TG levels. In the present study, we investigated plasma apoAV l Show more
Increased triglyceride (TG) occurs in patients with acute coronary syndrome (ACS), and apolipoprotein AV (apoAV) has been shown to lower TG levels. In the present study, we investigated plasma apoAV level and its relationship with TG and C-reactive protein (CRP) in ACS patients. A total of 459 subjects were recruited and categorized into control group (n = 116), stable angina (SA) group (n = 115), unstable angina group (n = 116) and acute myocardial infarction group (n = 112). Plasma apoAV level was measured by a sandwich ELISA assay. Compared with controls ((100.27 +/- 22.44) ng/ml), plasma apoAV was decreased in SA patients ((76.54 +/- 16.91) ng/ml) but increased in patients with unstable angina ((330.89 +/- 66.48) ng/ml, P < 0.05) or acute myocardial infarction ((368.66 +/- 60.53) ng/ml, P < 0.05). Inverse correlations between apoAV and TG were observed in the control or stable angina groups (r = -0.573 or -0.603, respectively, P < 0.001), whereas positive correlations were observed in the patients with unstable angina or acute myocardial infarction (r = 0.696 or 0.690, respectively, P < 0.001). Furthermore, a positive relationship between apoAV and CRP was observed in the ACS patients but not in the non-ACS subjects. The plasma apoAV concentration is increased and positively correlates with TG and CRP in ACS patients. Show less
no PDF
APOA5
Xian-sheng HUANG, Shui-ping ZHAO, Qian ZHANG +2 more · 2009 · Atherosclerosis · Elsevier · added 2026-04-24
Dyslipidemia is common in patients with acute coronary syndromes (ACS) but the mechanism remains unclear. Apolipoprotein AV (apoAV), a novel member of apolipoprotein family, is involved in lipid metab Show more
Dyslipidemia is common in patients with acute coronary syndromes (ACS) but the mechanism remains unclear. Apolipoprotein AV (apoAV), a novel member of apolipoprotein family, is involved in lipid metabolism. This study was to investigate plasma apoAV level and its association with lipids and high-sensitivity C-reactive protein (hs-CRP) in ACS patients. ACS patients (n=228) and healthy volunteers (n=232) were included. Plasma apoAV levels were measured by an ELISA method. Compared with controls, ACS patients had higher plasma apoAV, hs-CRP, triglycerides, total cholesterol and LDL cholesterol, as well as lower HDL cholesterol. Interestingly, a positive correlation was observed between apoAV and triglycerides in ACS patients, as compared with a negative correlation in controls. Notably, logistic regression analysis showed that plasma apoAV level was an independent predictor of ACS (OR=0.82, 95% CI 0.70-0.95, p<0.05). Furthermore, both apoAV and triglycerides were positively associated with hs-CRP in ACS patients. However, no significant correlations between apoAV and cholesterol including total cholesterol, HDL cholesterol and LDL cholesterol were observed in ACS patients. Thus, apoAV is an independent predictor of ACS although increased plasma apoAV level is positively correlated with triglycerides in ACS patients. Moreover, plasma cholesterol levels are not influenced by apoAV in ACS patients. Show less
no PDF DOI: 10.1016/j.atherosclerosis.2008.11.019
APOA5
Guo-Xin Hu, Hong-Yu Zhou, Xing-Wang Li +8 more · 2009 · The Journal of steroid biochemistry and molecular biology · Elsevier · added 2026-04-24
Androgen deprivation is commonly used in the treatment of metastatic prostate cancer. The (-)-gossypol enantiomer has been demonstrated as an effective inhibitor of Bcl-2 in the treatment of prostate Show more
Androgen deprivation is commonly used in the treatment of metastatic prostate cancer. The (-)-gossypol enantiomer has been demonstrated as an effective inhibitor of Bcl-2 in the treatment of prostate cancer. However, the mechanism of gossypol as an inhibitor of androgen biosynthesis is not clear. The present study compared (+)- and (-)-gossypols in the inhibition of 3beta-hydroxysteroid dehydrogenase (3beta-HSD) and 17beta-HSD isoform 3 (17beta-HSD3) in human and rat testes. Gossypol enantiomers were more potent inhibitors of rat 3beta-HSD with IC(50)s of approximately 0.2microM compared to 3-5microM in human testes. However, human 17beta-HSD3 was more sensitive to inhibition by gossypol enantiomers, with IC(50)s of 0.36+/-0.09 and 1.13+/-0.12 for (-)- and (+)-gossypols, respectively, compared to 3.43+/-0.46 and 10.93+/-2.27 in rat testes. There were species- and enantiomer-specific differences in the sensitivity of the inhibition of 17beta-HSD3. Gossypol enantiomers competitively inhibited both 3beta-HSD and 17beta-HSD3 by competing for the cofactor binding sites of these enzymes. Gossypol enantiomers, fed orally to rats (20mg/kg), inhibited 3beta-HSD but not 17beta-HSD3. This finding was consistent with the in vitro data, in which rat 3beta-HSD was more sensitive to gossypol inhibition than rat 17beta-HSD3. As the reverse was true for the human enzymes, gossypol might be useful for treating metastatic prostate cancer. Show less
no PDF DOI: 10.1016/j.jsbmb.2009.02.004
HSD17B12
Jun Lv, Xin Lu, Xiao-dan Jiang +5 more · 2009 · Nan fang yi ke da xue xue bao = Journal of Southern Medical University · added 2026-04-24
To express and purify the fusion protein of extracellular domain of human Ig domain-containing, neurite outgrowth inhibitor (Nogo) receptor-interacting protein-1 (LINGO-1(aa76-319)) in prokaryotic cel Show more
To express and purify the fusion protein of extracellular domain of human Ig domain-containing, neurite outgrowth inhibitor (Nogo) receptor-interacting protein-1 (LINGO-1(aa76-319)) in prokaryotic cells and prepare the rabbit anti-LINGO-1 polyclonal antibody (pAb). The 732 bp DNA sequence of hLINGO-1(aa76-319) was obtained from pCMV-SPORT6 by PCR and inserted into pET30a(+) plasmid to construct the prokaryotic expression plasmid pET30a(+)-hLINGO-1(aa76-319), which was subsequently transformed into E.coli. The target fusion protein was expressed with IPTG induction and purified by Ni(2+)-NTA affinity chromatography column. The antiserum against hLINGO-1(aa76-319) was obtained from the rabbits immunized with hLINGO-1(aa76-319), and the titer of the pAb was determined using enzyme linked immunosorbent assay (ELISA) and its specificity identified using Western blotting. The prokaryotic expression plasmid pET30a(+)-hLINGO-1(aa76-319) was constructed successfully. Efficient expression of the target fusion protein was achieved with IPTG induction at the optimal concentration of 0.4 mmol/L and culture temperature at 37 degrees celsius; for 2.5 h. The hLINGO-1(aa76-319) fusion protein was effectively expressed in E.coli as inclusion bodies, and the soluble protein was obtained through denaturation and refolding procedures, and the purified fusion protein showed a purity above 90%. The titer of the anti-hLINGO-1(aa76-319) pAb obtained by immunizing the rabbits with the purified protein reached 1:1.6x10(6), and Western blotting confirmed its good specificity. The fusion protein hLINGO-1(aa76-319) with high purity has been obtained and the anti-hLINGO-1(aa76-319) pAb obtained shows a high titer and good specificity, which provide important experimental basis for further functional investigation of LINGO-1. Show less
no PDF
LINGO1
Sha Mi, Robert H Miller, Wei Tang +18 more · 2009 · Annals of neurology · Wiley · added 2026-04-24
Repair of demyelinated axons in diseases such as multiple sclerosis requires activation of the myelination program in existing or newly recruited oligodendrocyte precursor cells (OPCs). The control of Show more
Repair of demyelinated axons in diseases such as multiple sclerosis requires activation of the myelination program in existing or newly recruited oligodendrocyte precursor cells (OPCs). The control of OPC differentiation and initiation of myelination during repair is poorly understood. In this study, we test the ability of anti-LINGO-1 reagents to promote myelination in vitro and remyelination in the rodent adult central nervous system in vivo. The effects of LINGO-1 antagonists on the differentiation of OPCs and the promotion of myelination has been assayed using a combination of coculture and slice culture preparations. Using three different animal models of demyelination and remyelination, we morphologically and functionally assessed the effects of LINGO-1 antagonists on OPC differentiation and myelin repair. The data indicate that in vitro treatment with antagonists of LINGO-1 promote OPC differentiation and myelination, whereas in vivo remyelination is accelerated in lysophosphatidylcholine- or cuprizone-induced demyelination. This remyelination is associated with enhanced OPC differentiation and functional recovery of conduction velocities in demyelinated axons. Our studies demonstrate that LINGO-1 antagonism promotes OPC differentiation and remyelination, and suggest LINGO-1 functions as an inhibitor of OPC differentiation to retard central nervous system remyelination. Show less
no PDF DOI: 10.1002/ana.21581
LINGO1
Ai-Rong Qian, Li-Fang Hu, Xiang Gao +7 more · 2009 · Bioelectromagnetics · Wiley · added 2026-04-24
The intense inhomogeneous magnetic fields acting on the diamagnetic materials naturally present in cells can generate strong magnetic forces. We have developed a superconducting magnet platform with l Show more
The intense inhomogeneous magnetic fields acting on the diamagnetic materials naturally present in cells can generate strong magnetic forces. We have developed a superconducting magnet platform with large gradient high magnetic field (LG-HMF), which can produce three magnetic force fields of -1360, 0, and 1312 T(2)/m, and three corresponding apparent gravity levels, namely 0, 1, and 2-g for diamagnetic materials. In this study, the effects of different magnetic force fields on osteoblast-like cells (MG-63 and MC3T3-E1) viability, microtubule actin crosslinking factor 1 (MACF1) expression and its association with cytoskeleton were investigated. Results showed that cell viability increased to different degrees after exposure to 0 or 1-g conditions for 24 h, but it decreased by about 30% under 2-g conditions compared with control conditions. An increase in MACF1 expression at the RNA or protein level was observed in osteoblast-like cells under the magnetic force field of -1360 T(2)/m (0-g) relative to 1312 T(2)/m (2-g). Under control conditions, anti-MACF1 staining was scattered in the cytoplasm and partially colocalized with actin filaments (AFs) or microtubules (MTs) in the majority of osteoblast-like cells. Under 0-g conditions, MACF1 labeling was concentrated at perinuclear region and colocalization was not apparent. The patterns of anti-MACF1 labeling on MTs varied with MTs' changing under LG-HMF environment. In conclusion, LG-HMF affects osteoblast-like cell viability, MACF1 distribution, expression, and its association with cytoskeleton to some extent. Show less
no PDF DOI: 10.1002/bem.20511
MACF1
Kai Gao, Hui Zhou, Lei Zhang +7 more · 2009 · PloS one · PLOS · added 2026-04-24
Saliva (oral fluids) is an emerging biofluid poised for detection of clinical diseases. Although the rationale for oral diseases applications (e.g. oral cancer) is intuitive, the rationale and relatio Show more
Saliva (oral fluids) is an emerging biofluid poised for detection of clinical diseases. Although the rationale for oral diseases applications (e.g. oral cancer) is intuitive, the rationale and relationship between systemic diseases and saliva biomarkers are unclear. In this study, we used mouse models of melanoma and non-small cell lung cancer and compared the transcriptome biomarker profiles of tumor-bearing mice to those of control mice. Microarray analysis showed that salivary transcriptomes were significantly altered in tumor-bearing mice vs. controls. Significant overlapping among transcriptomes of mouse tumors, serum, salivary glands and saliva suggests that salivary biomarkers have multiple origins. Furthermore, we identified that the expression of two groups of significantly altered transcription factors (TFs) Runx1, Mlxipl, Trim30 and Egr1, Tbx1, Nr1d1 in salivary gland tissue of melanoma-bearing mice can potentially be responsible for 82.6% of the up-regulated gene expression and 62.5% of the down-regulated gene expression, respectively, in the saliva of melanoma-bearing mice. We also showed that the ectopic production of nerve growth factor (NGF) in the melanoma tumor tissue as a tumor-released mediator can induce expression of the TF Egr-1 in the salivary gland. Taken together, our data support the conclusion that upon systemic disease development, significant changes can occur in the salivary biomarker profile. Although the origins of the disease-induced salivary biomarkers may be both systemic and local, stimulation of salivary gland by mediators released from remote tumors plays an important role in regulating the salivary surrogate biomarker profiles. Show less
📄 PDF DOI: 10.1371/journal.pone.0005875
MLXIPL
Zhan-feng Ma, Wen-ling Liu, Da-Yi Hu +16 more · 2009 · Zhonghua xin xue guan bing za zhi · added 2026-04-24
To screen the MYBPC3 gene mutations in Han Chinese patients with hypertrophic cardiomyopathy (HCM). Sixty-six patients with HCM were enrolled for the study. The exons in the functional regions of MYBP Show more
To screen the MYBPC3 gene mutations in Han Chinese patients with hypertrophic cardiomyopathy (HCM). Sixty-six patients with HCM were enrolled for the study. The exons in the functional regions of MYBPC3 were amplified with PCR and the products were sequenced. Four novel mutations and four common polymorphisms were identified in this patient cohort. A Lys301fs mutation in exon10 was evidenced in a H30, and when he was 47 years old, he had the chest tightness, shortness of breath with septal hypertrophy of 18.7mm; a Asp463stop mutation in exon17 was detected in a H48, he was 24 years old 24-year-old when a medical examination showed ventricular septal hypertrophy of 15.4 mm; both Gly523Arg mutation in exon18 and Tyr847His mutation in exon26 were found in a H53 with onset age 36 years old, feeling chest tightness after excise and his ventricular septal hypertrophy was 27 mm that time. MYBPC3 mutations occurred in 4.5% patients in this cohort. These mutations were not found in 100 non-HCM control patients. MYBPC3 mutation is presented in a small portion of Han Chinese patients with HCM. Show less
no PDF
MYBPC3
Baihua Hu, Raymound Unwalla, Michael Collini +6 more · 2009 · Bioorganic & medicinal chemistry · Elsevier · added 2026-04-24
A series of cinnolines/quinolines was prepared and it was found that 4-phenyl-cinnoline/quinolines with either a 2',3' or 2',5'-disubstituted benzyloxy moiety or the 1-Me-7-indole methoxy moiety on th Show more
A series of cinnolines/quinolines was prepared and it was found that 4-phenyl-cinnoline/quinolines with either a 2',3' or 2',5'-disubstituted benzyloxy moiety or the 1-Me-7-indole methoxy moiety on the meta position of the 4-phenyl ring showed good binding selectivity for LXRbeta over LXRalpha. The LXRbeta binding selective modulators displayed good activity for inducing ABCA1 gene expression in J774 macrophage cell line and poor efficacy in the LXRalpha Gal4 functional assay. 26, 37 and 41 were examined for their ability to induce SREBP-1c gene expression in Huh-7 liver cell line and they were weak partial agonists. Show less
no PDF DOI: 10.1016/j.bmc.2009.04.012
NR1H3
Xin Ma, Yan-wei Hu, Zhong-cheng Mo +6 more · 2009 · Cardiovascular drugs and therapy · Springer · added 2026-04-24
The Niemann-Pick C1 (NPC1) protein regulates the transport of cholesterol from late endosomes/lysosomes to other compartments responsible for maintaining intracellular cholesterol homeostasis. Liver X Show more
The Niemann-Pick C1 (NPC1) protein regulates the transport of cholesterol from late endosomes/lysosomes to other compartments responsible for maintaining intracellular cholesterol homeostasis. Liver X receptors (LXRs) operate as cholesterol sensors which may protect from cholesterol overload by increasing the amount of free cholesterol in the plasma membrane through inducing NPC1 expression. NO-1886 has been proven to be highly effective at increasing liver X receptor alpha expression and promoting cellular cholesterol efflux. In this study, the effects of NO-1886 on NPC1 expression were investigated in THP-1 macrophage-derived foam cells. Results showed that NO-1886 markedly increased expression of NPC1 at both mRNA level and protein level in a dose-dependent and time-dependent manner. Cellular cholesterol content was decreased while cholesterol efflux was increased by NO-1886 treatment. In addition, LXR alpha was also up-regulated by NO-1886 treatment. And LXR alpha small interfering RNA completely abolished the promotion effect which was induced by NO-1886. These results provide evidence that NO-1886 up-regulates expression of NPC1 through LXR alpha pathway in THP-1 macrophage- derived foam cells. Show less
no PDF DOI: 10.1007/s10557-009-6165-8
NR1H3
Xin-rui Hao, Dong-li Cao, Yan-wei Hu +6 more · 2009 · Atherosclerosis · Elsevier · added 2026-04-24
Interferon gamma (IFN-gamma) is an immunomodulatory and anti-microbial cytokine, which has a variety of proatherogenic effects. It has been reported that IFN-gamma can down-regulate ABCA1 expression. Show more
Interferon gamma (IFN-gamma) is an immunomodulatory and anti-microbial cytokine, which has a variety of proatherogenic effects. It has been reported that IFN-gamma can down-regulate ABCA1 expression. However, its mechanism is elusive. In the present study, we have investigated the effect of IFN-gamma on ABCA1 expression and cholesterol efflux in THP-1 macrophage-derived foam cells. IFN-gamma decreased ABCA1 expression at both transcriptional and translational levels in a dose-dependent manner. Cellular cholesterol content was increased while cholesterol efflux was decreased by IFN-gamma treatment. Liver X receptor alpha (LXRalpha), which can regulate the expression of ABCA1, was also down-regulated by IFN-gamma treatment. LXRalpha-specific activation by LXRalpha agonist almost compensated the down-regulation of ABCA1 expression by IFN-gamma, while siRNA of LXRalpha led to down-regulation of ABCA1 expression more significantly than IFN-gamma. IFN-gamma induced phosphorylation of STAT1 and expression of STAT1alpha in the nucleus, which was inhibited by a JAK inhibitor AG-490. Treatment with STAT1 siRNA further enhanced down-regulation of LXRalpha mRNA by IFN-gamma. Furthermore, AG-490 and STAT1 siRNA almost compensated the effect of IFN-gamma on ABCA1 expression and cholesterol efflux. In conclusion, IFN-gamma may first down-regulate expression of LXRalpha through the JAK/STAT1 signaling pathway and then decrease expression of ABCA1 and cholesterol efflux in THP-1 macrophage-derived foam cells. Therefore, our study may be useful in understanding the critical effect of IFN-gamma in pathogenesis of atherosclerosis. Show less
no PDF DOI: 10.1016/j.atherosclerosis.2008.07.029
NR1H3
Y Dai, C Hu, Y Huang +3 more · 2008 · Lupus · SAGE Publications · added 2026-04-24
Our objective was to analyze the changes in the protein expression profiles of peripheral blood mononuclear cells (PBMCs) in patients with systemic lupus erythematosus (SLE). Peripheral blood was obta Show more
Our objective was to analyze the changes in the protein expression profiles of peripheral blood mononuclear cells (PBMCs) in patients with systemic lupus erythematosus (SLE). Peripheral blood was obtained from patients with SLE and healthy controls. 2-D gel electrophoresis was performed, and gels were silver-stained. Differentially expressed protein spots were detected, some of which were identified by MALDI-TOF spectrometry. Match rates of 71% +/- 4% and 72% +/- 4% were gotten for control and patient gels, respectively. 791 +/- 17 spots were detected for control gels and 781 +/- 17 for patient gels. Eleven protein spots were up-regulated, and 9 protein spots were down-regulated in patients with SLE. Five differentially expressed proteins were identified as immunoglobulin J chain, apolipoprotein A-IV precursor, calprotectin L1H and zinc finger protein subfamily 1A (all up-regulated) and glutathione S-transferase (down-regulated), some of which had previously been shown to play a potential role in the pathogenesis of SLE. We conclude there are significant changes in the 2-D maps of PBMCs in patients with SLE and applying this proteomic approach may be a useful way to gain novel insights into SLE. Show less
no PDF DOI: 10.1177/0961203308089444
APOA4
Lung-An Hsu, Yu-Lin Ko, Chi-Jen Chang +3 more · 2008 · Clinical chemistry and laboratory medicine · added 2026-04-24
The -1131T>C polymorphism in the apolipoprotein gene A5 (APOA5) was found to be associated with increased levels of plasma triglyceride and decreased levels of high-density lipoprotein cholesterol (HD Show more
The -1131T>C polymorphism in the apolipoprotein gene A5 (APOA5) was found to be associated with increased levels of plasma triglyceride and decreased levels of high-density lipoprotein cholesterol (HDL-C), which are characteristic dyslipidemic components of metabolic syndrome. This study aimed to identify a link between this polymorphism and the risk of metabolic syndrome. The sample population comprised 615 unrelated subjects, 18.7% of whom had metabolic syndrome. Genotypes were determined via polymerase chain reaction, restriction mapping with MseI, and gel electrophoresis. A significantly higher level of triglycerides and a lower level of HDL-C were noted in carriers of the -1131C allele than in the non-carriers (p<0.001 and p=0.044, respectively). The frequency of the -1131C allele in the metabolic syndrome-affected subjects was significantly higher than that of the group of unaffected subjects (37.4% vs. 27.7%, p=0.004). Even after adjusting for age, gender, smoking, regular exercise, and waist-to-hip ratio, the APOA5 -1131C allele carriers remained significantly associated with an increased risk of metabolic syndrome (OR=1.77, 95% CI, 1.13-2.77; p=0.012). These results indicate that the association of APOA5 -1131T>C polymorphism with dyslipidemia can also contribute to an increased susceptibility to metabolic syndrome in the Chinese, as a result of its effect on triglyceride metabolism. Show less
no PDF DOI: 10.1515/CCLM.2008.352
APOA5
Qing-Ling Fu, Bing Hu, Wutian Wu +3 more · 2008 · Investigative ophthalmology & visual science · added 2026-04-24
LINGO-1 is a functional member of the Nogo66 receptor (NgR1)/p75 and NgR1/TROY signaling complexes that prevent axonal regeneration through RhoA in the central nervous system. LINGO-1 also promotes ce Show more
LINGO-1 is a functional member of the Nogo66 receptor (NgR1)/p75 and NgR1/TROY signaling complexes that prevent axonal regeneration through RhoA in the central nervous system. LINGO-1 also promotes cell death after neuronal injury and spinal cord injury. The authors sought to examine whether blocking LINGO-1 function with LINGO-1 antagonists promotes retinal ganglion cell (RGC) survival after ocular hypertension and optic nerve transection. An experimental ocular hypertension model was induced in adult rats using an argon laser to photocoagulate the episcleral and limbal veins. LINGO-1 expression in the retinas was investigated using immunohistochemistry and Western blotting. Soluble LINGO-1 protein (LINGO-1-Fc) and anti-LINGO-1 mAb 1A7 were injected into the vitreous body to examine their effects on RGC survival after ocular hypertension and optic nerve transection. Signal transduction pathways mediating neuroprotective LINGO-1-Fc effects were characterized using Western blotting and specific kinase inhibitors. LINGO-1 was expressed in RGCs and up-regulated after intraocular pressure elevation. Blocking LINGO-1 function with LINGO-1 antagonists, LINGO-1-Fc and 1A7 significantly reduced RGC loss 2 and 4 weeks after ocular hypertension and also promoted RGC survival after optic nerve transection. LINGO-1-Fc treatment blocked the RhoA, JNK pathway and promoted Akt activation. LINGO-1-Fc induced Akt phosphorylation, and the survival effect of LINGO-1 antagonists was abolished by Akt phosphorylation inhibitor. The authors demonstrated that blocking LINGO-1 function with LINGO-1 antagonists rescues RGCs from cell death after ocular hypertension and optic nerve transection. They also delineated the RhoA and PI-3K/Akt pathways as the predominant mediator of LINGO-1-Fc neuroprotection in this paradigm of RGC death. Show less
no PDF DOI: 10.1167/iovs.07-1199
LINGO1
Qing Wang, Min Xia, Chi Liu +8 more · 2008 · Life sciences · Elsevier · added 2026-04-24
Anthocyanins belong to a large and widespread group of water-soluble phytochemicals and exhibit potent antioxidative and anti-inflammatory properties; however, the molecular mechanisms of these bioche Show more
Anthocyanins belong to a large and widespread group of water-soluble phytochemicals and exhibit potent antioxidative and anti-inflammatory properties; however, the molecular mechanisms of these biochemical actions mediated by anthocyanins remain unclear. In this study, our data show that pretreatment of THP-1 macrophages with Cyanidin-3-O-beta-glucoside (C3G) for 12 h can enhance the expression and transcriptional activities of the nuclear receptor peroxisome proliferator-activated receptor gamma (PPARgamma) and liver X receptor alpha (LXRalpha). Furthermore, pretreatment of these cells with C3G for 12 h causes dose-dependent inhibition of lipopolysaccharide (LPS)-induced nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) at both the mRNA and protein levels together with a decrease in nitric oxide (NO) and prostaglandin E(2) (PGE(2)) production. Consequently, addition of geranylgeranyl pyrophosphate ammonium salt (GGPP), an LXRalpha antagonist, significantly downregulates the inhibitory effect of C3G on LPS-induced iNOS and COX-2 expression in THP-1 macrophages, whereas the PPARgamma antagonist GW9662 has no effect. Further investigation revealed that LXRalpha might interfere with LPS-induced iNOS and COX-2 expression by suppressing the functional activation of nuclear factor-kappaB (NF-kappaB), not - as was previously proposed - by reducing NF-kappaB nuclear translocation. Taken together, these results indicate that LXRalpha activation has an essential role in the anti-inflammatory property of C3G. Moreover, they provide new insight into the molecular basis for the anti-inflammatory property of anthocyanins. Show less
no PDF DOI: 10.1016/j.lfs.2008.05.017
NR1H3
Baihua Hu, Elaine Quinet, Rayomand Unwalla +11 more · 2008 · Bioorganic & medicinal chemistry letters · Elsevier · added 2026-04-24
A series of potent and binding selective LXRbeta agonists was developed using the previously reported non-selective LXR ligand WAY-254011 as a structural template. With the aid of molecular modeling, Show more
A series of potent and binding selective LXRbeta agonists was developed using the previously reported non-selective LXR ligand WAY-254011 as a structural template. With the aid of molecular modeling, it was found that 2,3-diMe-Ph, 2,5-diMe-Ph, and naphthalene substituted quinoline acetic acids (such as quinoline 33, 37, and 38) showed selectivity for LXRbeta over LXRalpha in binding assays. Show less
no PDF DOI: 10.1016/j.bmcl.2007.11.013
NR1H3
Zhao-Yan Jiang, Paolo Parini, Gösta Eggertsen +7 more · 2008 · Journal of lipid research · added 2026-04-24
Cholesterol supersaturation of bile is one prerequisite for gallstone formation. In the present study of Chinese patients with gallstones, we investigated whether this phenomenon was correlated with t Show more
Cholesterol supersaturation of bile is one prerequisite for gallstone formation. In the present study of Chinese patients with gallstones, we investigated whether this phenomenon was correlated with the hepatic expression of genes participating in the metabolism of cholesterol and bile acids. Twenty-two nonobese, normolipidemic patients (female-male, 11:11) with gallstones were investigated with 13 age- and body mass index-matched gallstone-free controls (female-male, 10:3). The bile from the gallstone patients had higher cholesterol saturation than that from the controls. The mRNA levels of ABCG5, ABCG8, and liver X receptor alpha (LXRalpha) in the gallstone patients were increased by 51, 59, and 102%, respectively, and significantly correlated with the molar percentage of biliary cholesterol and cholesterol saturation index (CSI). The mRNA and protein levels of the hepatic scavenger receptor class B type I (SR-BI) were increased, and a significant correlation was found between the protein levels and the CSI. No differences were recorded between the two groups concerning the hepatic synthesis of cholesterol, bile acids, and esterification of cholesterol. Our results suggest that the upregulation of ABCG5/ABCG8 in gallstone patients, possibly mediated by increased LXRalpha, may contribute to the cholesterol supersaturation of bile. Our data are consistent with the possibility that increased amounts of biliary cholesterol may originate from plasma HDL cholesterol by enhanced transfer via SR-BI. Show less
no PDF DOI: 10.1194/jlr.M700295-JLR200
NR1H3